查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102787

癌症基因治療市場：全球市場預測，2026-2032年

Cancer Gene Therapy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症基因治療市場將成長至 118.1 億美元，複合年成長率為 19.96%。

主要市場統計數據
基準年 2025 33億美元
預計年份：2026年 39.7億美元
預測年份：2032年 118.1億美元
複合年成長率 (%) 19.96%

癌症基因治療執行摘要

癌症基因療法正在改變腫瘤學的模式，它不再只依賴細胞毒性療法，而是從基因、細胞和免疫層面著手，解決疾病問題。這個領域涵蓋了多種策略，包括體外和體內基因轉移、病毒和非病毒載體、基因修飾細胞療法、溶瘤病毒、RNA療法、抑癌基因替換、免疫查核點調控和基因組編輯。載體工程技術的進步、生產控制的改進、伴隨診斷、基於生物標記的患者篩選以及先進醫療產品和細胞療法監管知識的積累，都為臨床研發提供了有力支撐。其中，骨髓惡性腫瘤領域最為活躍，基因修飾的免疫細胞已在特定患者群體中展現出持續的療效；固體癌領域則致力於克服腫瘤異質性、免疫抑制、基質屏障、遞送限制和抗原逃脫等難題。癌症基因療法為醫療保健系統帶來了兩大挑戰。它涉及加快獲取可能具有變革意義的療法，同時還要應對低溫運輸物流、長期追蹤、藥物安全監測、專業臨床基礎設施以及基於價值的報銷等方面的複雜要求。隨著腫瘤學向精準醫療轉型，基因療法正成為癌症治療整體體系中的關鍵支柱，它將分子診斷、個人化治療方案設計、免疫工程和真實世界數據（REW）的生成聯繫起來。

癌症基因治療前景的變革性變化

癌症基因治療領域正經歷結構性轉型，從實驗性介入轉向臨床整合的精準腫瘤學。首要變化是治療平台的多元化。基因修飾T細胞療法、腫瘤浸潤淋巴細胞療法、溶瘤病毒療法、基因靜默技術、癌症疫苗和基因組編輯等技術都在同步發展。這種多元化降低了對單一療法的依賴，並促進了與查核點抑制劑、標靶治療、放射療法和傳統化療的聯合治療策略。第二個轉折點是遞送技術的革新。慢病毒、逆轉錄病毒、腺病毒、腺結合病毒、脂質奈米顆粒和聚合物遞送系統在有效載荷能力、組織親和性、免疫抗原性、持久性和生產規模化等方面都得到了改進和最佳化。第三個變化是治療早期階段的應用以及在更廣泛的腫瘤類型中的應用，這得益於基於生物標記的篩檢、微量殘存疾病評估和適應性檢測設計。監管機構日益重視療效測試、可比較方案、長期安全性監測和上市後證據，這反映了生物醫學和基因改造療法的複雜性。生產環節也在經歷變革，封閉式系統加工、自動化、分散式生產模式以及品質源於設計 (QbD) 實踐降低了變異性並增強了供應鏈的韌性。這些變化共同將腫瘤基因治療重新定義為一個精準的、基於平台的領域，其臨床結果取決於分子生物學、免疫學、生產科學、數位分析以及醫療保健系統現狀的整合。

人工智慧對癌症基因治療的累積影響

人工智慧 (AI) 對癌症基因治療的影響日益顯著，涵蓋從發現和開發到生產、臨床應用以及治療後監測的各個環節。在發現階段，機器學習模型被用於識別腫瘤相關抗原、預測新抗原的免疫抗原性、確定基因標靶的優先順序、設計引導 RNA、最佳化載體有效載荷以及模擬脫靶效應。在轉化研究中，AI 支持基因組學、轉錄組學、蛋白質組學、單細胞測序、空間生物學、成像、病理學和臨床資料集等多體學學數據的整合，幫助研究人員了解腫瘤微環境、免疫逃脫和抗藥性機制。在臨床開發中，AI 驅動的患者分層可以透過將分子譜與治療機制相匹配來提高臨床實驗參與者選擇的準確性。在難以進行隨機試驗的情況下，合成對照方法和真實世界數據分析也能增強證據的產生。製造領域也是人工智慧的關鍵應用領域，人工智慧可以監控程式參數、預測批次間差異、輔助出貨檢驗、最佳化自體細胞療法的治療方案安排，並加強偏差管理。在臨床環境中，人工智慧驅動的決策支援能夠解讀複雜的分子檢測報告、合格評估、預測毒性風險，並對細胞激素釋放症候群、神經毒性、免疫逃脫和復發進行個人化監測。人工智慧的累積影響並非取代科學和臨床判斷，而是加速這一以生物複雜性、個人化製造和關鍵治療決策為特徵的領域中循證決策的發展。負責任的實施需要檢驗的演算法、透明的資料管治、偏差緩解、網路安全、互通性和合規性。

癌症基因治療的關鍵區域見解

在亞太地區，大規模的患者群體、不斷擴大的腫瘤學基礎設施、活性化的臨床試驗活動以及各國對生物技術投入的不斷成長，都為癌症基因療法的發展提供了支持。中國、日本、韓國、印度和澳洲在細胞療法研究、載體生產、再生醫學監管和監管現代化方面發揮核心作用。北美仍然是臨床應用、先進醫療監管、大學醫院網路、專科癌症中心和醫保報銷試驗的重要中心，美國和加拿大支持高水準的臨床試驗參與、長期安全性監測、分子診斷技術的應用以及真實世界數據（RWE）基礎設施建設。在拉丁美洲，能力建設正透過腫瘤學出版中心、公私合作以及擴大基因組檢測和分子診斷的覆蓋範圍而不斷推進，但成本效益、出版管道、專業生產和公共醫療保險覆蓋範圍仍然是巴西、墨西哥和其他主要醫療體系面臨的主要限制因素。歐洲受益於成熟的先進療法法規結構、跨境科學合作、完善的癌症登記系統和健全的公共醫療體系，但具體實施情況因各國醫療技術評估流程、報銷標準、醫院認證要求以及細胞療法遞送系統的發展而有所不同。在中東，尤其是在面臨醫療轉型挑戰的國家，對三級醫療、基因組醫學計劃、國家癌症戰略和專科癌症治療項目的投資正在推進，但長期進展取決於人力資源開發、數據基礎設施、本地生產能力和治療能力。非洲正處於引入癌症基因療法的早期準備階段，其優先需求集中在癌症診斷、病理檢測的可及性、臨床試驗參與度、低溫運輸系統、腫瘤領域的人力資源開發以及公平的夥伴關係，以防止基因組創新與獲得基本癌症治療之間的差距進一步擴大。

各主要團體對引進癌症基因療法的看法

由於癌症負擔日益加重、醫療旅遊中心不斷擴張以及三級癌症診療能力的提升，東協正崛起為癌症基因治療領域具有戰略意義的重要區域。儘管成員國在監管協調、治療費用可及性、分子檢測普及程度以及專家能力方面仍存在差異，但東協成員國之間仍存在差距。海灣合作理事會（GCC）正透過國家基因組計劃、大力投資的醫院系統、數位化醫療策略以及對精準腫瘤學日益成長的興趣來推進癌症基因治療的發展。用於引進先進療法的區域中心的重要性日益凸顯，尤其是在那些擁有跨境醫療模式和集中式專科設施的地區。歐盟透過對先進療法藥物的監管、集中式科學評估、跨境研究網路、公共研究經費以及嚴格的藥物安全監測要求，為癌症基因治療提供了最完善的環境之一。然而，病人能否獲得治療取決於國家健保報銷系統和醫院認證流程。金磚國家在科學、臨床和生產製造方面發揮著至關重要的作用。其中，中國和印度推動了規模擴張，巴西和南非為區域臨床能力做出了貢獻，而俄羅斯則維護腫瘤研究基礎設施。然而，監管成熟度、醫療資金和本地生產能力的差異導致了基因治療技術應用速度的差異。七國集團（G7）透過監管科學、臨床指南、學術研究、智慧財產權框架、醫療技術評估和長期追蹤模式，繼續對癌症基因治療標準的製定產生重大影響。北約成員國，特別是那些擁有先進生物醫學基礎設施的國家，為供應鏈安全、生物安全措施、臨床研究協調和韌性醫療體係做出了貢獻。隨著基因療法依賴複雜生技藥品的生產、安全的數據交換和受保護的物流網路，所有這些因素都變得日益重要。

主要國家癌症基因治療的發展趨勢

美國已建立起癌症基因治療實用化的領先環境，這得益於其廣泛的臨床實驗室網路、先進的細胞和基因治療主導管道、專業的癌症中心、便捷的分子診斷以及強大的真實世界證據（RWE）體系。加拿大透過學術癌症研究、公共醫療保健評估框架、國家癌症登記系統以及對公平獲取先進治療的日益關注，為癌症基因治療的發展做出了貢獻。墨西哥正在擴大其癌症治療能力並參與臨床研究，但由於公立和私立醫療保健體系的差異、報銷制度的差異、出版體系的差異以及是否存在專業中心，其治療機會不盡相同。巴西在拉丁美洲先進癌症治療的發展中發揮核心作用，這得益於其癌症實驗室、臨床研究能力以及分子診斷的廣泛應用，儘管成本、物流和基礎設施仍然是推廣應用的挑戰。英國憑藉其在基因組學領域的領先地位、國家癌症數據資產、系統化的衛生技術評估以及綜合臨床研究網路，將證據生成和成本效益作為其推廣應用的核心。德國是歐洲領先的先進療法研究中心，擁有強大的醫院腫瘤學專業技術、臨床試驗和生物製造能力。法國透過其國家癌症戰略、學術研究、轉化醫學網路以及歐洲框架內的先進療法法規，大力支持癌症基因療法。俄羅斯已在腫瘤學領域建立了科學基礎和臨床能力，但國際合作趨勢、技術取得和監管協調等因素正在影響其發展速度。義大利和西班牙在歐洲癌症治療和臨床研究中發揮著重要作用，其區域醫院網路、移植和細胞治療方面的專業知識以及保險報銷流程都影響著療法的普及和應用速度。中國正在建立一個非常活躍的癌症基因治療生態系統，這得益於大規模的細胞治療臨床研究、不斷擴展的生物製造能力、醫院腫瘤學網路以及不斷完善的法律規範體系。印度擁有巨大的長期潛力，這得益於其龐大的患者群體、生物技術領域的人才儲備、不斷壯大的國內細胞治療舉措以及完善的癌症中心基礎設施。然而，確保成本效益和基礎設施標準化仍然是重中之重。日本擁有成熟的再生醫學和先進療法法規環境，這得益於其強大的轉化研究能力、對藥物安全監測的嚴格要求以及人口老齡化帶來的癌症治療需求成長。澳洲以其高品質的臨床試驗、可靠的監管機構、公私合作研究模式以及區域性研究夥伴關係關係而聞名。韓國正透過投資生物技術、先進的醫院系統、數位醫療能力以及專為精準腫瘤學和細胞療法發展量身定做的生產製造技術，不斷鞏固其在該領域的地位。

為癌症基因治療領域的領導者提供的實用建議

產業領導者應優先考慮平台韌性、臨床差異化和准入準備。首先，投資於能夠增強腫瘤靶向性、降低免疫抗原性並實現重複給藥的遞送技術，尤其是在固體癌。其次，透過整合基因組分析、免疫表現型分析、微量殘存疾病追蹤、伴隨診斷和真實世界臨床結果，最佳化生物標記策略並識別最有可能從治療中獲益的患者。第三，從一開始就設計符合監管機構對持久性、安全性、可比較性、療效測試和長期追蹤要求的臨床項目。第四，透過封閉式系統自動化、檢驗的分析方法、柔軟性源自於設計 (QbD) 框架、穩健的身分鏈管理以及自體和異體供應鏈的緊急時應對計畫，建構生產彈性。第五，透過展示臨床價值、生活品質 (QOL) 影響、治療路徑效率和持續反應，而非僅依賴短期終點，來準備早期准入證據。第六，我們將與癌症中心、診斷實驗室、保險公司、病患團體、物流供應商和數位健康平台建立夥伴關係，以支援公告發布、合格評估、治療協調和監測。第七，我們將採取負責任的人工智慧管治，以確保演算法透明度、資料隱私、網路安全、互通性和臨床有效性。最後，領導者應推動全球臨床實驗室更參與並提升其能力，使癌症基因治療的進步不限於資源豐富的醫療體系。

調查方法

本執行摘要基於二手研究和行業分析，使用了經驗證的公共領域資源，包括監管指南、臨床實驗室註冊資訊、同行評審的癌症和基因治療文獻、衛生監管機構出版刊物、癌症流行病學資源、科學檢驗資訊披露資訊、治療指南、藥物安全監測要求以及公開的政策文件。研究方法強調對臨床證據、監管趨勢、技術趨勢、醫療基礎設施指標、生產考慮和區域可近性進行資訊來源三角驗證。透過對治療方法、給藥平台評估、監管管道考察、臨床開發流程圖、生產和品質考量、生物標記應用以及醫療系統準備的評估，探討了關鍵主題。透過檢驗癌症醫療基礎設施、先進療法的監管、基因組醫學計劃、臨床研究能力、報銷機制、專科治療中心的可用性以及長期追蹤能力，獲得了區域、群體和國家層面的洞察。本調查方法不包括市場規模和估計、收入預測、市場佔有率計算和未來預測。相反，它側重於與癌症基因治療的策略規劃、臨床引入和基於政策的決策相關的循證定性見解。

結論

癌症基因療法正從腫瘤學領域的一個專業前沿分支發展成為精準癌症治療的核心要素。這項進展得益於載體設計、基因修飾免疫細胞平台、基因組編輯、基於生物標記的治療選擇、人工智慧驅動的分析以及法律規範的日趨完善等方面的進步。然而，為了實現廣泛的臨床應用，仍需解決諸多挑戰，例如固體癌的療效、生產的規模化、安全性監測、降低經濟負擔、簡化發表流程以及確保公平取得。擁有完善的腫瘤學基礎設施、基因組診斷技術、先進的醫療法規、專業的治療網路以及真實世界數據（REW）能力的地區和國家，更有利於將這些療法整合到常規臨床實踐中。同時，新興的醫療保健系統需要加大對診斷、人才、物流以及臨床研究的投入。對於產業領導者而言，未來的發展之路需要嚴謹的證據產生、負責任的技術應用、卓越的生產製造以及整個腫瘤學生態系統的協作。隨著醫療保健系統尋求更永續、更個人化、更基於機制的癌症治療方法，癌症基因療法的戰略重要性預計將持續成長。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模/成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG/永續性分析
  • 中斷風險情景
  • 投資報酬率,成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症基因治療市場：依載體類型分類

  • 非病毒載體
    • 脂質奈米顆粒
    • 物理方法
    • 聚合物奈米粒子
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第8章 癌症基因治療市場：依治療類型分類

  • 體外
  • 體內

第9章：癌症基因治療市場：依適應症分類

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 攝護腺癌

第10章 癌症基因治療市場：依階段分類

  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業
  • 臨床前

第11章 癌症基因治療市場：依最終用戶分類

  • 醫院和診所
  • 腫瘤中心
  • 研究所

第12章 癌症基因治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 癌症基因治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 癌症基因治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum BIoTechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis SA
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.
Product Code: MRR-B1685377A6FA

The Cancer Gene Therapy Market is projected to grow by USD 11.81 billion at a CAGR of 19.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.30 billion
Estimated Year [2026] USD 3.97 billion
Forecast Year [2032] USD 11.81 billion
CAGR (%) 19.96%

Cancer Gene Therapy Executive Summary

Cancer gene therapy is reshaping oncology by addressing disease at the genetic, cellular, and immune-system levels rather than relying solely on cytotoxic intervention. The field spans ex vivo and in vivo gene delivery, viral and non-viral vectors, gene-modified cell therapies, oncolytic viruses, RNA-based approaches, tumor suppressor replacement, immune checkpoint modulation, and genome-editing-enabled strategies. Clinical momentum is supported by advances in vector engineering, improved manufacturing controls, companion diagnostics, biomarker-guided patient selection, and expanding regulatory experience with advanced therapy medicinal products and cellular therapies. The most active areas include hematologic malignancies, where engineered immune cells have demonstrated durable responses in selected patient populations, and solid tumors, where innovation is focused on overcoming tumor heterogeneity, immune suppression, stromal barriers, delivery limitations, and antigen escape. For healthcare systems, cancer gene therapy presents a dual imperative: accelerating access to potentially transformative treatments while managing complex requirements for cold chain logistics, long-term follow-up, pharmacovigilance, specialized clinical infrastructure, and value-based reimbursement. As oncology shifts toward precision medicine, gene therapy is becoming a critical pillar in the broader cancer treatment continuum, linking molecular diagnostics, individualized treatment design, immune engineering, and real-world evidence generation.

Transformative Shifts in the Cancer Gene Therapy Landscape

The cancer gene therapy landscape is undergoing a structural transition from experimental intervention to clinically integrated precision oncology. The first major shift is the diversification of therapeutic platforms, with engineered T-cell therapies, tumor-infiltrating lymphocyte approaches, oncolytic viral therapies, gene-silencing technologies, cancer vaccines, and genome editing advancing in parallel. This diversification is reducing dependence on a single modality and encouraging combination strategies with checkpoint inhibitors, targeted therapies, radiation, and conventional chemotherapy. The second shift is the evolution of delivery science. Improved lentiviral, retroviral, adenoviral, adeno-associated viral, lipid nanoparticle, and polymer-based delivery systems are being optimized for payload capacity, tissue tropism, immunogenicity, persistence, and manufacturing scalability. The third shift is the move toward earlier-line use and broader tumor coverage, supported by biomarker enrichment, minimal residual disease assessment, and adaptive trial designs. Regulators are increasingly emphasizing potency assays, comparability protocols, long-term safety monitoring, and post-authorization evidence, reflecting the complexity of living and gene-modifying therapies. Manufacturing is also transforming, with closed-system processing, automation, decentralized production models, and quality-by-design practices reducing variability and strengthening supply resilience. Together, these changes are repositioning cancer gene therapy as a precision, platform-based discipline where clinical outcomes depend on the integration of molecular biology, immunology, manufacturing science, digital analytics, and health system readiness.

Cumulative Impact of Artificial Intelligence on Cancer Gene Therapy

Artificial intelligence is increasingly influencing cancer gene therapy across discovery, development, manufacturing, clinical deployment, and post-treatment monitoring. In discovery, machine learning models are used to identify tumor-associated antigens, predict neoantigen immunogenicity, prioritize genetic targets, design guide RNAs, optimize vector payloads, and model off-target effects. In translational research, AI supports multi-omics integration across genomics, transcriptomics, proteomics, single-cell sequencing, spatial biology, imaging, pathology, and clinical datasets, helping researchers understand tumor microenvironments, immune escape, and resistance mechanisms. In clinical development, AI-enabled patient stratification can improve trial enrichment by aligning molecular profiles with therapy mechanisms, while synthetic control methods and real-world data analytics may strengthen evidence generation where randomized trials are challenging. Manufacturing is another critical application area, as AI can monitor process parameters, predict batch variability, support release testing, improve autologous cell therapy scheduling, and enhance deviation management. In clinical practice, AI-driven decision support can help interpret complex molecular reports, assess eligibility, forecast toxicity risk, and personalize monitoring for cytokine release syndrome, neurotoxicity, immune escape, and relapse. The cumulative impact of artificial intelligence is not the replacement of scientific and clinical judgment, but the acceleration of evidence-based decision-making in a field defined by biological complexity, individualized production, and high-stakes therapeutic decisions. Responsible adoption requires validated algorithms, transparent data governance, bias mitigation, cybersecurity, interoperability, and regulatory alignment.

Key Regional Insights Across Cancer Gene Therapy

In Asia-Pacific, cancer gene therapy development is supported by large patient populations, expanding oncology infrastructure, rising clinical trial activity, and growing national investment in biotechnology, with China, Japan, South Korea, India, and Australia playing central roles in cell therapy research, vector manufacturing, regenerative medicine regulation, and regulatory modernization. North America remains a major center for clinical translation, advanced therapy regulation, academic hospital networks, specialized cancer centers, and reimbursement experimentation, with the United States and Canada supporting high levels of trial participation, long-term safety surveillance, molecular diagnostics adoption, and real-world evidence infrastructure. Latin America is building capacity through oncology referral centers, public-private research collaborations, and increasing access to genomic testing and molecular diagnostics, although affordability, referral pathways, specialized manufacturing, and public-sector coverage remain key constraints across Brazil, Mexico, and other major healthcare systems. Europe benefits from a mature advanced therapy regulatory framework, cross-border scientific collaboration, established cancer registries, and strong public healthcare systems, while implementation varies due to country-level health technology assessment processes, reimbursement criteria, hospital qualification requirements, and cell therapy delivery readiness. The Middle East is investing in tertiary care, genomic medicine initiatives, national cancer strategies, and specialized oncology programs, especially in countries with healthcare transformation agendas, but long-term progress depends on workforce development, data infrastructure, local manufacturing capability, and treatment capacity. Africa is at an earlier stage of cancer gene therapy readiness, with priority needs centered on cancer diagnostics, pathology access, clinical trial inclusion, cold chain systems, oncology workforce expansion, and equitable partnerships that avoid widening the gap between genomic innovation and basic cancer care access.

Key Group Insights for Cancer Gene Therapy Adoption

ASEAN is emerging as a strategically important region for cancer gene therapy because of rising cancer burden, expanding medical tourism hubs, and improving tertiary oncology capabilities, although regulatory harmonization, affordability, molecular testing access, and specialist capacity remain uneven across member states. The GCC is advancing through national genomics programs, high-investment hospital systems, digital health strategies, and growing interest in precision oncology, making regional centers increasingly relevant for advanced therapy adoption, particularly where cross-border care models and centralized specialist facilities are available. The European Union provides one of the most structured environments for cancer gene therapy through advanced therapy medicinal product regulation, centralized scientific assessment, cross-national research networks, public research funding, and strong pharmacovigilance expectations, though patient access depends on national reimbursement and hospital certification pathways. BRICS countries collectively represent substantial scientific, clinical, and manufacturing relevance, with China and India driving scale, Brazil and South Africa contributing regional clinical capacity, and Russia maintaining oncology research infrastructure, while differences in regulatory maturity, healthcare funding, and local production capability create varied adoption trajectories. G7 countries remain highly influential in shaping cancer gene therapy standards through regulatory science, clinical guidelines, academic research, intellectual property frameworks, health technology assessment, and long-term follow-up models. NATO member countries, particularly those with advanced biomedical infrastructure, contribute to supply chain security, biosecurity policy, clinical research collaboration, and resilient healthcare systems, all of which are increasingly relevant as gene therapy depends on complex biologics manufacturing, secure data exchange, and protected logistics networks.

Key Country Insights in Cancer Gene Therapy

The United States is a leading environment for cancer gene therapy translation, supported by extensive clinical trial networks, advanced regulatory pathways for cellular and gene therapies, specialized oncology centers, molecular diagnostics access, and strong real-world evidence systems. Canada contributes through academic cancer research, public healthcare evaluation frameworks, national cancer registries, and growing interest in equitable access to advanced therapies. Mexico is expanding oncology capabilities and clinical research participation, with access shaped by public-private healthcare differences, reimbursement variability, referral infrastructure, and the availability of specialized centers. Brazil is central to Latin American advanced oncology development, supported by cancer institutes, clinical research capacity, and increasing molecular diagnostics adoption, while cost, logistics, and infrastructure remain implementation challenges. The United Kingdom combines genomics leadership, national cancer data assets, structured health technology assessment, and integrated clinical research networks, making evidence generation and cost-effectiveness central to adoption. Germany is a major European hub for advanced therapy research, hospital-based oncology expertise, clinical trial execution, and biomanufacturing capability. France supports cancer gene therapy through national oncology strategy, academic research, translational medicine networks, and advanced therapy regulation within the European framework. Russia has established oncology science and clinical capacity, though international collaboration dynamics, technology access, and regulatory alignment influence development pathways. Italy and Spain are important contributors to European cancer care and clinical research, with regional hospital networks, transplant and cell therapy expertise, and reimbursement processes influencing access and implementation speed. China has become a highly active cancer gene therapy ecosystem with substantial clinical investigation in cell therapies, expanding biomanufacturing, hospital-based oncology networks, and evolving regulatory oversight. India offers significant long-term potential due to its large patient base, biotechnology talent, growing domestic cell therapy initiatives, and expanding cancer center infrastructure, while affordability and infrastructure standardization remain central priorities. Japan provides a mature regulatory environment for regenerative medicine and advanced therapies, supported by strong translational research, pharmacovigilance expectations, and aging-population oncology demand. Australia is recognized for high-quality clinical trials, regulatory credibility, public-private research collaboration, and regional research partnerships. South Korea is strengthening its position through biotechnology investment, advanced hospital systems, digital health capabilities, and manufacturing expertise aligned with precision oncology and cell therapy development.

Actionable Recommendations for Cancer Gene Therapy Leaders

Industry leaders should prioritize platform resilience, clinical differentiation, and access readiness. First, invest in delivery technologies that improve tumor targeting, reduce immunogenicity, and support repeat dosing, particularly for solid tumors. Second, strengthen biomarker strategies by integrating genomic profiling, immune phenotyping, minimal residual disease tracking, companion diagnostics, and real-world outcomes to identify the patients most likely to benefit. Third, design clinical programs that address regulators' expectations for durability, safety, comparability, potency testing, and long-term follow-up from the outset. Fourth, build manufacturing flexibility through closed-system automation, validated analytics, quality-by-design frameworks, robust chain-of-identity controls, and contingency planning for autologous and allogeneic supply chains. Fifth, prepare access evidence early by demonstrating clinical value, quality-of-life impact, care pathway efficiency, and durability of response without relying solely on short-term endpoints. Sixth, establish partnerships with cancer centers, diagnostic laboratories, payers, patient organizations, logistics providers, and digital health platforms to support referral, eligibility assessment, treatment coordination, and monitoring. Seventh, adopt responsible AI governance to ensure algorithmic transparency, data privacy, cybersecurity, interoperability, and clinical validation. Finally, leaders should expand global trial inclusion and capacity-building to ensure cancer gene therapy advances do not remain limited to highly resourced healthcare systems.

Research Methodology

This executive summary is based on secondary research and industry analysis using verified public-domain sources, including regulatory guidance, clinical trial registries, peer-reviewed oncology and gene therapy literature, health authority publications, cancer epidemiology resources, scientific conference disclosures, treatment guidelines, pharmacovigilance requirements, and publicly available policy documents. The research approach emphasizes data triangulation across clinical evidence, regulatory developments, technology trends, healthcare infrastructure indicators, manufacturing considerations, and regional access dynamics. Key themes were assessed through therapeutic modality analysis, delivery platform evaluation, regulatory pathway review, clinical development mapping, manufacturing and quality considerations, biomarker adoption, and health system readiness assessment. Regional, group, and country insights were developed by examining oncology infrastructure, advanced therapy regulation, genomic medicine initiatives, clinical research capacity, reimbursement mechanisms, availability of specialized treatment centers, and long-term follow-up capabilities. The methodology excludes market sizing, revenue estimation, market share calculation, and forecasting, focusing instead on evidence-backed qualitative intelligence relevant to strategic planning, clinical adoption, and policy-informed decision-making in cancer gene therapy.

Conclusion

Cancer gene therapy is advancing from a specialized frontier of oncology into a core component of precision cancer care. Progress is being driven by improved vector design, engineered immune-cell platforms, genome editing, biomarker-guided treatment selection, AI-enabled analytics, and maturing regulatory oversight. However, broad clinical impact depends on solving persistent challenges in solid tumor efficacy, manufacturing scalability, safety monitoring, affordability, referral efficiency, and equitable access. Regions and countries with strong oncology infrastructure, genomic diagnostics, advanced therapy regulation, specialized treatment networks, and real-world evidence capabilities are better positioned to integrate these therapies into routine care, while emerging systems require investment in diagnostics, workforce, logistics, and clinical research inclusion. For industry leaders, the path forward requires disciplined evidence generation, responsible technology adoption, manufacturing excellence, and collaboration across the oncology ecosystem. Cancer gene therapy will continue to gain strategic importance as healthcare systems pursue more durable, personalized, and mechanism-driven approaches to cancer treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Gene Therapy Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Nonviral Vectors
    • 7.2.1. Lipid Nanoparticles
    • 7.2.2. Physical Methods
    • 7.2.3. Polymeric Nanoparticles
  • 7.3. Viral Vectors
    • 7.3.1. Adeno-Associated
    • 7.3.2. Adenoviral
    • 7.3.3. Lentiviral
    • 7.3.4. Retroviral

8. Cancer Gene Therapy Market, by Therapy Type

  • 8.1. Introduction
  • 8.2. Ex Vivo
  • 8.3. In Vivo

9. Cancer Gene Therapy Market, by Indication

  • 9.1. Introduction
  • 9.2. Hematological Cancers
    • 9.2.1. Leukemia
    • 9.2.2. Lymphoma
    • 9.2.3. Myeloma
  • 9.3. Solid Tumors
    • 9.3.1. Breast Cancer
    • 9.3.2. Colorectal Cancer
    • 9.3.3. Lung Cancer
    • 9.3.4. Prostate Cancer

10. Cancer Gene Therapy Market, by Stage

  • 10.1. Introduction
  • 10.2. Clinical Trials
    • 10.2.1. Phase I
    • 10.2.2. Phase II
    • 10.2.3. Phase III
  • 10.3. Commercial
  • 10.4. Preclinical

11. Cancer Gene Therapy Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals And Clinics
  • 11.3. Oncology Centers
  • 11.4. Research Laboratories

12. Cancer Gene Therapy Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Cancer Gene Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Gene Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abeona Therapeutics Inc.
  • 16.2. Adaptimmune Therapeutics PLC
  • 16.3. Adverum Biotechnologies, Inc.
  • 16.4. AGC Biologics
  • 16.5. Alnylam Pharmaceuticals, Inc.
  • 16.6. American Gene Technologies Inc.
  • 16.7. Amgen Inc.
  • 16.8. AnGes, Inc.
  • 16.9. Astellas Pharma Inc.
  • 16.10. Biogen Inc.
  • 16.11. bluebird bio, Inc.
  • 16.12. Cellectis S.A.
  • 16.13. CRISPR Therapeutics AG
  • 16.14. Danaher Corporation
  • 16.15. Editas Medicine, Inc.
  • 16.16. F. Hoffmann-La Roche Ltd.
  • 16.17. Gilead Sciences, Inc.
  • 16.18. Intellia Therapeutics
  • 16.19. Ionis Pharmaceuticals, Inc.
  • 16.20. Johnson & Johnson
  • 16.21. Merck KGaA
  • 16.22. Mustang Bio, Inc.
  • 16.23. Novartis AG
  • 16.24. Orchard Therapeutics PLC
  • 16.25. Poseida Therapeutics, Inc.
  • 16.26. Sangamo Therapeutics, Inc.
  • 16.27. Sarepta Therapeutics, Inc.
  • 16.28. Sibiono GeneTech Co. Ltd.
  • 16.29. Syncona Limited
  • 16.30. ViGeneron GmbH
  • 16.31. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NONVIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NONVIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NONVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHYSICAL METHODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHYSICAL METHODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHYSICAL METHODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POLYMERIC NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POLYMERIC NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLYMERIC NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADENO-ASSOCIATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADENO-ASSOCIATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADENO-ASSOCIATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADENOVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADENOVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADENOVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LENTIVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LENTIVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LENTIVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RETROVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RETROVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RETROVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 336. SPAIN CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 337. SPAIN CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 338. SPAIN CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 339. SPAIN CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 347. CHINA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 348. CHINA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 349. CHINA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 350. CHINA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 354. INDIA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 355. INDIA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. INDIA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 357. INDIA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 358. INDIA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 359. INDIA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 360. INDIA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 361. INDIA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 362. JAPAN CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 363. JAPAN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. JAPAN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 365. JAPAN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 366. JAPAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. JAPAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 368. JAPAN CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2